Effect of ashwagandha (Withania somnifera) extract with Sominone (Somin-On™) to improve memory in adults with mild cognitive impairment: A randomized, double-blind, placebo-controlled study.

Abstract

Background: Mild cognitive impairment (MCI) is a condition in which people have memory or thinking problems than other people of their age. This study evaluated the effectiveness and safety of ashwagandha extract standardized with Sominone (Somin-On™) in enhancing memory and cognitive functioning in adults with MCI.

Methods: In this randomized double-blind, placebo-controlled pilot study, 40 subjects with MCI were randomized in a 1:1 ratio to receive either Somin-On™ (250 mg daily) or a placebo for 60 days. The outcome measures, improvement in memory and other cognitive functions after 30 and 60 days were assessed using Montreal Cognitive Assessment (MoCA); Mini-mental state examination (MMSE); Wechsler Memory Scale-III (WMS-III)); and Shepard mental rotation task.

Results: Subjects treated with Somin-On™ showed significant improvements in immediate memory, general memory, working memory and visuospatial processing and the response assessed using WMS-III after 30 and 60 days outperforming the placebo group. Scores on the Shepard Mental Rotation test in Somin-On™ group showed a significant rise by 12.22% at 30 days and 31.67% at 60 days, from baseline. Significant improvement was observed with Somin-On™ in memory assessment scales viz. MoCA (7.83% at 30 days and 14.77% at 60 days, from baseline) and MMSE (9.26% at 30 days and 19.21% at 60 days, from baseline) compared to placebo group.

Conclusions: The supplementation of Somin-On™ is an effective therapy to improve the immediate, general and working memory, as well as cognitive functions like attention and information processing speed in adults with MCI.